Research and Development
Pfizer Australia works with some of Australia's best and brightest scientists, clinicians and investigators to discover and develop new medicines to prevent, treat and cure human diseases.
Pfizer is strongly committed to R&D investment and, globally, expects to spend around US$6.5 billion on R&D activities in 2013.
We invite you to explore this site to learn more about our
investigator initiated research,
competitive research grants and
compound transfer program (compound/pure substance supply for research purposes).
Collaboration with the medical community is at the core of our commitment to build on Australia's exceptional research capabilities. We recognise that together we can make a difference.
Our objective is to provide outstanding clinical researchers and medical scientists with additional opportunities to establish world-class research programs in Australia.
Together, we are working to:
- Encourage the pursuit of medical research and science as an important and rewarding career pathway.
Enhance the contribution of Australian clinical research and medical science to our social and economic well-being.
Contribute to the continued development of the local pharmaceutical industry.
Provide additional funding opportunities for local medical research and innovation that seeks to identify new treatment targets or new therapies.
Enhance the opportunities for Australian medical science and clinical research to contribute to the global pharmaceutical development process.
Identify world-class research in Australia with the potential to provide unique or complementary research leads or tools to assist in its drug discovery program.
Build enduring relationships between Australian medical innovators, government, academia, clinicians and industry, by developing an environment of cooperation and mutual trust.
Develop a model that establishes a template for effective interaction between the local research and biotechnology communities, and the global pharmaceutical industry.